Cipla Limited ("Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albendazole Tablets 200mg from the United States Food and Drug Administration (US FDA).
Cipla's Albendazole Tablets 200mg is AB-rated generic therapeutic equivalent version of Impax Laboratories, Inc.'s, Albenza®. It is an anthelmintic drug indicated for use in Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
According to IQVIA (IMS Health), Albenza® had US sales of approximately $99M for the 12-month period ending July 2018. The product is available for shipping immediately.
Shares of CIPLA LTD. was last trading in BSE at Rs.660.6 as compared to the previous close of Rs. 659.45. The total number of shares traded during the day was 196878 in over 2333 trades.
The stock hit an intraday high of Rs. 670.15 and intraday low of 639.45. The net turnover during the day was Rs. 130004475.